Ex Vivo Validation of Cancer Drug Combinations

Progress Toward a Universal Vaccine for Aging-Related Diseases: now with tests on 30 cancers

We are excited to share our latest progress on developing a universal vaccine for aging-related diseases. Our approach positions Agemica at the forefront of cutting-edge AI, bioinformatics, and robust experimental data. 

In Vitro and Ex Vivo Validation of Cancer Drug Combinations

Over the past two years, we’ve analyzed data from 1,000 cancer cells, uncovering key mechanisms driving cancer progression. Through in vitro studies, we identified seven drug combinations that effectively eradicated cancer cells at nanomolar doses. These therapies were further validated ex vivo, where we tested their safety and efficacy across 30 3D tumor organoid models derived from human tumors.

Using co-cultures with human immune cells, our six lead therapies demonstrated remarkable efficacy:

   •       Eradication of up to 100% of cancer cells in 12 cancer types.

   •       Superior performance compared to positive controls.

   •       Significant reductions in tumor volume across all tested cancers.

These therapies target cancers including Liver, Pancreatic, Melanoma, Kidney, Stomach, Triple-Negative Breast, Adenocarcinoma, Large Cell Lung, Osteosarcoma, Colon, Uterine, and the rare Pleuramesothelioma. Each therapy is effective across multiple cancer types, addressing the complexity and diversity of solid tumors.

The charts below illustrates the performance of six combination therapies tested across various cancers in ex-vivo studies, with each therapy represented by a unique color. Tumor volume and cell death were measured seven days after drug treatment. A positive control—a highly cytotoxic drug that kills all cancer cells—was used as a benchmark to evaluate the efficacy of our therapies.

In many cases, our therapies reduced tumor volume significantly more than the positive control. For instance:

• In kidney cancer, Therapy 4 reduced tumor volume by 72%, compared to 36% for the positive control. This represents a 37% greater reduction than the benchmark; shown as 137% on the chart.
• In stomach cancer, Therapy 3 achieved a tumor volume reduction of 107% relative to the positive control. Additionally, it induced 100% cell death, meaning no viable cancer cells were detected seven days post-treatment. This measure of cell death is absolute, not comparative.

Furthermore, 100% cell death was observed in cases of liver cancer, stomach cancer, triple-negative breast cancer, and pleural mesothelioma (a rare disease). In pancreatic cancer and lung adenocarcinoma, cell death reached 94% and 84%, respectively, while tumor volume reductions outperformed the positive control in both cases.

These results validate the efficacy of our combination therapies in ex-vivo models. The next steps include confirming these findings in animal models using humanized mice (particularly the ones marked with *) and advancing five of the therapies (Therapies 2-6) toward IND approval in dogs.

This data underscores the potential of our therapies to outperform conventional treatments, paving the way for further development and regulatory approval.